12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Welcome to the 26th edition of our newsletter on developments in the automotive industry published b...
Read More >
Restrictions on a contractor's rights to subcontract works are common across industry forms of contr...
Read More >
The Subletting and Subcontracting Fair Practices Act (Public Contract Code section 4100 et seq.), al...
Read More >
We have enjoyed the benefits of the longest economic expansion in U.S. history – over 120 months of...
Read More >
For contractors and subcontractors, late payments can be an all-too-familiar part of the constructio...
Read More >
In today’s edition of Daily Compliance News: 1. In a print ad campaign, Boeing said it is “Truly ...
Read More >